Poster display Poster Display session

68P - MicroRNA-21 functions as a prognosis predictor in head of pancreas tumor

Presentation Number
68P
Lecture Time
17:10 - 17:10
Speakers
  • Fuat Aksoy (Bursa, TR)
Session Name
Location
Foyer La Scene, Paris Marriott Rive Gauche, Paris, France
Date
05.03.2018
Time
17:10 - 18:00
Authors
  • Fuat Aksoy (Bursa, TR)
  • Seçil Aksoy (Bursa, TR)
  • Berrin Tunca (Bursa, TR)
  • Halit Ziya Dundar (Bursa, TR)
  • Pinar Sarkut (Bursa, TR)
  • Yilmaz Ozen (Bursa, TR)
  • Unal Egeli (Bursa, TR)
  • Gulsah Cecener (Bursa, TR)
  • Omer Yerci (Bursa, TR)
  • Ekrem Kaya (Bursa, TR)

Abstract

Background

Pancreatic ductal adenocarnoma (PDAC) is the fourth leading cause of cancer related death in men and women.15 Approximately 60-70% of PDACs arise in the head of the pancreas. Since the early diagnosis of head of the pancreas tumors is difficult, patients are frequently at an advanced stage at the time of diagnosis and have extremely short survival. Furthermore, the mechanism of pathogenesis in PDAC is not completely understood and there are currently no effective therapies. Recent studies demonstrated that miRNAs play critical roles in various types of tumors including PDAC and thereby has high diagnostic value for screening and great clinical value for cancer therapy. The aim of the present study was to determine the expression profile of miRNAs in head of pancreas and examine its association with prognosis.

Methods

A total of 56 patients who underwent pancreaticoduodenectomy for head of pancreas were analyzed for 12 different miRNAs by RT-PCR.

Results

miR-21 and miR-10b were 11.78-fold (P = 0.004) and 9.62-fold (P = 0.021) higher, and the miR-143 expression was 5.49-fold lower (P = 0.0412) in tumor tissues compared with normal tissues. The over expression of miR-21 was related with lymphatic invasion (P = 0.0203). Moreover, high miR-21 expression was an independent poor prognostic factor for overall survival (P = 0.0242).

Conclusions

The elevated expression of miR-21 may be involved in the progression of head of pancreas tumors and may therefore be considered a prognostic factor for patients with poor prognosis.

Legal entity responsible for the study

Ekrem Kaya

Funding

Has not received any funding

Disclosure

All authors have declared no conflicts of interest.

Collapse